Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10662727 | 0.87 | CA5A (0.52) | CA5AHPGDKDM4EALDH1A1KLKB1 | |
| SCHEMBL17283078 | 0.85 | TP53 (0.49) | CA5APTGESALDH1A1TP53 | |
| SCHEMBL15937242 | 0.84 | HTT (0.49) | HTTHPGDKDM4EALDH1A1KMT2A | |
| SCHEMBL11010308 | 0.80 | CA5A (0.41) | CA5AKDM4EALDH1A1PTGDR2SLC22A12 | |
| SCHEMBL2368039 | 0.80 | KDM4E (0.50) | HTTHPGDNPC1KDM4EALDH1A1 | |
| SCHEMBL795210 | 0.79 | HPGD (0.68) | HTTHPGDKLKB1CYP19A1KMT2A | |
| SCHEMBL2368342 | 0.78 | POLB (0.53) | HTTHPGDALDH1A1KLKB1PTGDR2 | |
| SCHEMBL9857412 | 0.75 | CA5A (0.55) | CA5AHPGDKDM4EALDH1A1KLKB1 | |
| SCHEMBL10670780 | 0.75 | TP53 (0.58) | HTTCA5APTGESALDH1A1TP53 | |
| SCHEMBL2367846 | 0.75 | HPGD (0.54) | HTTHPGDPTGESKDM4EKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207938-A1 | Process for the Preparation of Rufinamide | CIPLA LIMITED (IN) | 2011-08-25 | — | — | US | claimed |
| EP-2334653-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | Cilpa Limited (IN) | 2011-06-22 | — | — | EP | claimed |
| WO-2010043849-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | CIPLA LIMITED (IN) | 2010-04-22 | — | — | WO | claimed |
| US-20140357871-A1 | PROCESS FOR PREPARATION OF RUFINAMIDE | LUPIN LIMITED (IN) | 2014-12-04 | — | — | US | disclosed |
| WO-2014121383-A1 | A PROCESS FOR THE PREPARATION OF RUFINAMIDE AND INTERMEDIATES THEREOF | APOTEX TECHNOLOGIES INC. (CA) | 2014-08-14 | — | — | WO | disclosed |
| WO-2013105029-A1 | PROCESS FOR PREPARATION OF RUFINAMIDE | LUPIN LIMITED (IN) | 2013-07-18 | — | — | WO | disclosed |
| US-8183269-B2 | Process for the preparation of rufinamide | CIPLA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| WO-2012032540-A1 | PROCESS FOR PREPARATION OF FLUORINATED TRIAZOLE COMPOUND | INDOCO REMEDIES LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-20110207938-A1 | Process for the Preparation of Rufinamide | CIPLA LIMITED (IN) | 2011-08-25 | — | — | US | disclosed |
| US-20110207938-A1 | Process for the Preparation of Rufinamide | CIPLA LIMITED (IN) | 2011-08-25 | — | — | US | disclosed |
| WO-2010043849-A8 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | CIPLA LIMITED (IN) | 2011-06-30 | — | — | WO | disclosed |
| EP-2334653-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | Cilpa Limited (IN) | 2011-06-22 | — | — | EP | disclosed |
| EP-2334653-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | Cilpa Limited (IN) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010043849-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | CIPLA LIMITED (IN) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010043849-A1 | PROCESS FOR THE PREPARATION OF RUFINAMIDE | CIPLA LIMITED (IN) | 2010-04-22 | — | — | WO | disclosed |
| US-4789680-A | Aralkyltriazole compounds | CIBA-GEIGY CORPORATION (US) | 1988-12-06 | — | — | US | disclosed |
| EP-0199262-A2 | Fluorinated benzyl triazole compounds | CIBA-GEIGY AG (CH) | 1986-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357871-A1 | PROCESS FOR PREPARATION OF RUFINAMIDE | ADH5, ADH1C, ADH1A | HTT 4169/4885CA5A 1070/4885HPGD 3367/4885 |
| US-20110207938-A1 | Process for the Preparation of Rufinamide | AZI2, F13A1, RTN3 | HTT 3970/4885CA5A 2300/4885HPGD 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.